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Abstract
Background: Mutations in filamin A (FLNa), an essential cytoskeletal protein with multiple binding partners, cause
developmental anomalies in humans.
Methodology/Principal Findings: We determined the structure of the 23
rd Ig repeat of FLNa (IgFLNa23) that interacts with
FilGAP, a Rac-specific GTPase-activating protein and regulator of cell polarity and movement, and the effect of the three
disease-related mutations on this interaction. A combination of NMR structural analysis and in silico modeling revealed the
structural interface details between the C and D b-strands of the IgFLNa23 and the C-terminal 32 residues of FilGAP.
Mutagenesis of the predicted key interface residues confirmed the binding constraints between the two proteins. Specific
loss-of-function FLNa constructs were generated and used to analyze the importance of the FLNa-FilGAP interaction in vivo.
Point mutagenesis revealed that disruption of the FLNa-FilGAP interface perturbs cell spreading. FilGAP does not bind FLNa
homologs FLNb or FLNc establishing the importance of this interaction to the human FLNa mutations. Tight complex
formation requires dimerization of both partners and the correct alignment of the binding surfaces, which is promoted by a
flexible hinge domain between repeats 23 and 24 of FLNa. FLNa mutations associated with human developmental
anomalies disrupt the binding interaction and weaken the elasticity of FLNa/F-actin network under high mechanical stress.
Conclusions/Significance: Mutational analysis informed by structure can generate reagents for probing specific cellular
interactions of FLNa. Disease-related FLNa mutations have demonstrable effects on FLNa function.
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Introduction
Filamin A (FLNa), encoded in humans and mice by a gene on
the X chromosome, is an abundant and ubiquitously expressed
non-muscle isoform of a family of actin cross-linking proteins [1].
Human melanoma cells lacking FLNa protein have unstable
plasma membranes, do not polarize or undergo locomotion, and
lack functional readouts for many of the identified FLNa-binding
partners, but restoring normal levels of FLNa in these deficient
cells rescues these functions [2–4]. Mutations of the FLNa gene
were first identified in human periventricular nodular heterotopia
(PVNH), an X-linked neuronal migration disorder that predom-
inantly affects females and results in embryonic lethality in
hemizygous males [5]. FLNa mutations are also associated with a
group of X-linked skeletal anomalies including frontometaphyseal
dysplasia (FMD) and cardiovascular defects such as familial
cardiac valvular dystrophy, the most common indication for
valvular surgery [6–8]. Complete loss of Flna in mice results in
embryonic lethality with bleeding and cardiovascular malforma-
tions [9,10]. This wide range of phenotypes is presumably
attributed to alterations of FLNa association with F-actin and its
binding partners, obstructing analysis of mechanisms underlying
FLNa pathogenesis.
FLNa is a dominant isoform of FLN family proteins (a, b and c)
and all isoforms are dimers of 270,280 kDa subunits that have N-
terminal spectrin-related actin-binding domains (srABD) separated
from C-terminal dimerization domain by 23 Ig repeats organized
as linear rod like strands. Two flexible hinges separate Ig repeats
15 and 16 and 23 and 24 [1,11]. FLNa cross-links F-actin to form
orthogonal networks that are responsible for cellular integrity and
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4928mechanics and attaches to membrane receptors including
adhesion molecules and ion channels. FLNa is also a scaffold for
numerous intracellular signaling intermediates. One of these,
FilGAP, has a pleckstrin homology domain for membrane lipid
binding, a GTPase-activating protein (GAP) domain, and a coiled-
coil domain responsible for FLNa binding [12]. FilGAP
specifically inactivates Rac in vivo, and this activity requires its
FLNa association. FilGAP controls cell polarity and movement
downstream of ROCK (Rho-kinase) [12].
Sorting out the contributions of these numerous interactions to
in vivo function requires structural information to enable use of
point mutant FLNa or partners lacking specific activities that are
otherwise fully functional. Here we describe the structure of the
FLNa/FilGAP complex and use the information to engineer
mutant protein incapable of expressing FilGAP function in vivo.
We also show that FilGAP interacts exclusively with FLNa among
its homologs and specific disruption of the FLNa-FilGAP
interaction perturbs cell spreading. Furthermore, we show that
two FLNa mutations found in PVNH and FMD patients disrupt
the folding of FLNa Ig repeat (IgFLNa) 23 and abolish FilGAP
binding, establishing a link between downstream signaling of Rac
and the patients’ pathogenesis.
Results
Identification of the FLNa-binding interface with FilGAP
Most of the protein constructs used for in vitro binding assay were
obtained in good yield and purity (Figure S1A). Figure 1A shows a
schematic diagram of FilGAP structure and demonstrates that the
C-terminal 100 residues (649–748 amino acid, aa) of FilGAP tagged
to a glutathione S-transferase-hexahistidine (GST-His) interact with
purified full-length FLNa in vitro, consistent with previous results
[12]. Further deletion constructs identified that the last 32 residues
(717–748aa,FilGAPC32),butnotresidues649–729ofthepredicted
coiled-coil domain by EMBnet COILS, are the FLNa-binding site
(Figure 1A). FilGAPC32 tagged to a maltose binding protein
followed by hexahistidine (MBP-His), however, did not pull down
with FLAG-FLNa (Figure 1B), and a synthetic peptide of
FilGAPC32 immobilized on Sepharose also did not precipitate
FLNa (data not shown). Analytical gel filtration demonstrated that
full-length FilGAP is a dimer and FilGAP lacking residues 649–725,
which contains the minimum FLNa-binding site (residues 726–734,
see below), is a monomer (Figure 1D and Figure S1B) and does not
form a tight complex with FLNa (Figure 1C). MBP-His-FilGAP
constructs containing residues 649–729 eluted as a decamer from
gel filtration columns, whereas MBP-His-FilGAPC32 was mono-
meric (Figure 1D and Figure S1B).
FLAG-tagged full-length FLNa pulled down full-length FilGAP
in vitro, and deletion of FLNa Ig repeat 23 abolished this
interaction (Figure 2A), consistent with previous results [12].
The interaction was diminished or abolished respectively by
deletion of hinge 2 and FLNa Ig repeat 24 (Figure 2A). Deletion of
the hinge 2 from the C-terminal of IgFLNa23-24 disrupted
FilGAP binding (Figure 2B). A hinge 2 plus IgFLNa24 construct
does not bind FilGAP (data not shown), indicating that hinge 2 is
not the FilGAP-binding site. Electron micrographs of mutant
FLNa constructs demonstrate that their shapes are indistinguish-
able from wild-type FLNa (Figure S2A), and these mutations do
not affect FLNa’s actin gelation activity (data not shown).
Solution structure of IgFLNa23 and mapping of the
FilGAP binding site
To map the binding site between IgFLNa23 and the C-terminal
peptide of FilGAP more closely, we first utilized solution state
NMR spectroscopy. All backbone amide signals were visible in the
15N-HSQC spectrum and nearly complete
1H-,
13C- and
15N-
resonance assignment of IgFLNa23 was achieved. Structure
determination yielded a structure of excellent quality. Almost all
residues reside on the favored areas of the Ramachandran plot
and the root mean square deviation (RMSD) values of the
structure family are very low (Table S1). The structure of
IgFLNa23 (Figure 3A) has a traditional Ig-like fold containing
two b-sheets with four b-strands in each. The structure is very
similar to the crystal and solution structures of IgFLNc23 (PDB
accession codes 2nqc and 2d7q) [13] and the solution structure of
IgFLNb23 (PDB accession code 2eec), and the RMSD of the best
possible alignment to these structures ranged from 0.7 to 1.2 A ˚.
The binding site of FilGAP was mapped by following chemical
shift changes in the
15N-HSQC NMR spectrum of IgFLNa23
upon addition of a synthetic FilGAP14 peptide,
723EQFFSTF-
GELTVEP
736. This shorter peptide was used instead of
FilGAPC32 because it was more soluble and thus better suited
for NMR studies. The interaction between IgFLNa23 and
FilGAP14 was in the fast-to-intermediate exchange region. Large
excess of peptide was needed to obtain clear changes in the
15N-
HSQC spectrum, suggesting that the affinity of IgFLNa23-
FilGAP14 interaction is weak. Many signals of IgFLNa23
disappeared or divided into multiple peaks in the course of
FilGAP14 titration, which made tracking of the chemical shift
changes difficult (Figure S3). The disappearance and division of
the signals was considered to be an indication of close proximity to
the binding site. All affected peaks are located close to the CD-
interface of IgFLNa23 (Figure 3B). Due to weakness of the
IgFLNa23-FilGAP14 interaction NMR spectroscopic structure
determination of the complex turned out to be unfeasible.
In silico model of the IgFLNa23-FilGAP complex
The CD faces of IgFLNa domains are common binding sites in
other known filamin interactions, including platelet glycoprotein (GP)
Iba binding to IgFLNa17 [14] and integrin b subunit cytoplasmic tail
bindingtoIgFLNa21 [15,16].AsFilGAP also interactedwiththeCD
faceof IgFLNa23, and the amino acid sequence of FilGAPC32 could
be aligned to the b-strand forming filamin-interacting peptides of
GPIba and integrins (Figure 3D), we modeled the FilGAPC32-
IgFLNa23 interaction based on the complex between IgFLNa17 and
aG P I b a peptide (Figures 3C and S4).
To verify that the interaction site with FilGAP is on the CD face
of IgFLNa23 we next mutated the hydrophopic M2474 to
negatively charged glutamate. Indeed, the point mutation
M2474E in IgFLNa23 abolished the interaction of full length
FLNa with recombinant FilGAP C-terminal fragment and with
full length FilGAP in vitro as predicted (Figure 4A). However, the
mutant filamin fully retained F-actin gelation activity, and its
morphology is indistinguishable from wild-type FLNa in electron
micrographs (Figure S2). NMR spectra also showed that M2474E
IgFLNa23 was fully folded (Figure S5). Thus, this mutation further
confirms that also in the context of full length FilGAP and FLNa,
the major FilGAP binding site is at the CD face of IgFLNa23.
To confirm the position of the b-strand forming segment of
FilGAP we mutated G730 and V734 to bulky aromatic residues.
G730W and V734Y substitutions perturbed the interaction of
FilGAP C-terminal fragments with the full-length FLAG-tagged
FLNa, conforming that these residues are indeed oriented towards
the interface (Figure 4B). The effect of V734Y substitution also
suggests that we modeled the b-strand interface in correct position of
FilGAP, since in our model this residue at the end of the b-strand.
The point mutation T728V had no effect in the interaction
(Figure 4B).
The FilaminA-FilGAP Complex
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To study the effects of FLNa and FilGAP mutations in vivo, full
length proteins were expressed in filamin-deficient M2 cells. Point
mutations of FLNa(M2474E) and FilGAP(V734Y) confirm that
these residues are critical for the binding partnering interaction in
vivo (Figure 5A). Transfection of either wild-type or V734Y mutant
hemaglutin (HA)-FilGAP in FLNa-null M2 cells suppressed
spreading on fibronectin-coated coverslips (Figure 5, B and C).
Figure 1. Localization of FLNa-FilGAP binding site. (A) Schematic representation of FilGAP and its truncation series. The pleckstrin-homology
(PH), GTPase-activating protein (GAP), and coiled-coil (CC) domains predicted by EMBnet COILS are shown. Right panel shows binding of FLAG-FLNa
to GST-FilGAP fragments illustrated in the left panel. Their interactions were analyzed by pull-down using FLAG-specific mAb immobilized on beads.
Bound protein was detected by immunoblotting using rabbit pAb to GST. (B) FilGAP fragments were fused to MBP-His-tag and their binding to FLAG-
FLNa were analyzed by pull-down using FLAG-specific mAb immobilized on beads. Bound protein was detected by immunoblotting using rabbit pAb
to MBP (C) His-tag FilGAP, or FilGAP lacking residues 649–725 (50 nM), were mixed with increasing amounts of FLAG-FLNa and immunoprecipitated
with FLAG-specific mAb immobilized on agarose. Bound FilGAP was detected by immunoblotting using anti-His-tag mouse mAb conjugated with
horse radish peroxidase (upper panel). The lower panel shows proteins visualized by CBB staining. (D) Molecular weight calibration curve obtained
with a Superose 6 10/300 gel filtration column. Molecular size standards (open circle) used were thyroglobulin (669 kDa), ferritin (440 kDa), aldolase
(158 kDa), conalbumin (75 kDa), and ovalbumin (43 kDa). Colored circles indicate the sizes of His-FilGAP, His-FilGAP lacking residues 649–725 or
FilGAP truncates fused to MBP-His-tag.
doi:10.1371/journal.pone.0004928.g001
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the effect of FilGAP, but expression of the mutant FilGAP did not
have this effect (Figure 5, B and C).
FilGAP specifically interacts with FLNa
Although the overall structure of IgFLNa23 is similar to those of
IgFLNb23 and IgFLNc23, immunoprecipitation of full-length
FLNb did not pull down full-length FilGAP in vitro (Figure 6A) and
the C-terminal of FilGAP interacted only with the C-terminal of
FLNa, not FLNb and c (Figure 6B). There are two amino acid
changes in the CD strands of FLNa versus FLNb: Ala2461 in
FLNa is substituted to Thr in FLNb and Asp2467 is Glu in FLNb.
(Figure 6C and D). A mutagenetic analysis demonstrated that the
A2461T substitution explains the specificity between FLNa and
FLNb (Figure 6E). It is likely that the principal interactions
between FLNb (and FLNa:A2461T) and FilGAP are disturbed by
the close proximity of two threonine side chains, since threonine is
a bulky residue adjacent to the main chain (in Figure 6D wild-type
FLNa is shown). In silico modeling suggests that amino acid
residues comprising the CD strands of IgFLNc23 do not define the
different specificity of FLNa and FLNc. Instead, substitution of
Y2483, which is involved in hydrophobic contacts with FilGAP
(Leu732 ) and surrounding amino acids in FLNa (Thr2454,
Cys2476) to histidine alters the interaction (Figure 6D). It is also
possible that Y2483 could donate a hydrogen-bond to the main-
chain oxygen of T733 in FilGAP, thus, stabilizing FilGAP binding
further. Such an interaction is not possible with a histidine in
position 2483. In vitro pull down experiments confirmed this
prediction (Figure 6E).
Effects of disease-related mutations of FLNa on its cross-
linking activity and FilGAP binding
A single de novo mutation, 7315C.A of the FLNA gene, which
results in PVNH and FMD in females, leads to two transcripts, an
L2439M point mutant and a deletion mutant lacking 7 amino
acids (D7: L2439-G2445) within repeat 23 (Figure 7A) [6,7].
Another de novo mutation in repeat 23 is 7447del9 (or D3: Y2483-
V2485, Figure 7A) and is associated with FMD in heterozygous
females [6]. We tagged these transcripts with EGFP at their N-
termini and expressed them in M2 cells with the same transfection
Figure 2. FLNa dimerization and hinge-2 are essential for high
avidity binding to FilGAP. (A) Full-length FilGAP was pulled down
with increasing amounts of wild-type and deletion mutants (A ¨23;
deletion of IgFLNa23, A ¨H2; deletion of FLNa hinge-2, A ¨24; deletion of
IgFLNa24) of FLNa tagged to FLAG immunoprecipitated with FLAG-
specific mAb immobilized on agarose. Bound FilGAP was detected by
immunoblotting using rabbit pAbs to FilGAP. (B) Left panel shows
purified MBP-FilGAP649-748, IgFLNa23-24, and IgFLNa23-24 A ¨H2
separated on SDS-PAGE and stained with CBB. Right panel; IgFLNa23-
24 or IgFLNa23-24 A ¨H2 were pulled down with amylose beads coated
with increasing amounts of the MBP-FilGAP649-748. Proteins were
visualized by CBB staining.
doi:10.1371/journal.pone.0004928.g002
Figure 3. The structure of IgFLNa23 and location of the FilGAP
binding interface. (A) A stereo image of superimposed backbone
traces of the 20 structures in NMR structure ensemble of IgFLNa23.
Cyan and red colors indicate b-strand and a-helical elements,
respectively. (B) FilGAP binding interface revealed by the chemical
shift changes in the
15N-HSQC NMR spectrum of IgFLNa23. The signals
that disappeared or divided upon peptide addition are indicated in red
on IgFLNa23. (C) The model of FilGAP peptide (green strand) interaction
based on the IgFLNa17-GPIba complex structure. Residues mutated in
this study are indicated. (D) The sequence alignment of the last 32
residues of FilGAP and FLNa-binding sites of GPIba ´ and a ˆ-integrins. The
alignment was generated using ClustalW program. The underline
indicates the peptide used for NMR titration. Amino acids indicated
with asterisks face a glove generated between the C and D strands of
the IgFLNa domain which are mainly involved in binding interaction.
doi:10.1371/journal.pone.0004928.g003
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in subcellular distribution. The expressed proteins were stable in
vivo at least up to 72 h (data not shown). FLAG-tagged-FLNa
mutants were expressed in sf-9 cells and purified in good yield
(Figure S1A). These mutations do not affect dimerization and
gelation activity of FLNa, although the D7 mutation slightly
diminished gelation activity (Figure 7B and Figure S2). Quanti-
tative rheological measurements of F-actin/FLNa networks
demonstrated that the L2439M point mutation does not affect
linear elasticity, maximum stress, or maximum nonlinear stiffness,
whereas D7 and D3 mutations diminished both the maximum
stress and maximum nonlinear stiffness, leading to networks that
rupture more easily under external mechanical stress (Figure 7B
and Figure S6). Figure 7C demonstrates that the D7 and D3
mutations completely eliminated FLNa interaction with FilGAP,
while no effect on FilGAP binding was detected with a point
mutation at L2439M. In line with these results L2439M
IgFLNa23 was fully folded when expressed alone in E. coli and
the NMR spectrum showed changes only near the mutated residue
(Figure S7). No NMR spectra of D7 and D3 IgFLNa23 could be
obtained due to sample aggregation, suggesting that these
deletions disrupt folding of the domain.
Structure of the FLNa-FilGAP complex
Since both the full-length FLNa and FilGAP are prone to
aggregate at high concentrations requisite for crystallization
(.2 mg/ml, data not shown), electron microscopy was used to
study their structure at low concentrations (Figure S8). Purified
FilGAP molecules appeared to be flexible dumbbells with two
globules (,14.2+/22.05 nm diameters; n=50) orienting at
various angles. The mixture of FLNa and FilGAP demonstrated
that the globules attached to the C-termini of FLNa molecules,
consistent with the biochemical findings, whereas FLNaM2474E
did not complex with FilGAP. Since gel-filtration revealed that
FilGAP molecules are dimers, each globule corresponds to one
FilGAP molecule (Figure 8 and Figure S8).
Discussion
We have mapped the binding site between the Rac-specific
GTPase-activating protein FilGAP and FLNa. We showed that
the residues 723–736 interact with the CD face of IgFLNa23.
Biochemical analysis indicated that dimerization of both FLNa
and FilGAP and FLNa hinge 2 are required for effective
interaction. Furthermore we showed that FilGAP is the first
interaction partner that is specific to FLNa, as no binding to FLNb
or FLNc was observed. Site-directed mutagenesis revealed that
abolishing the FLNa-FilGAP interaction perturbs cell spreading.
Disease-causing mutations that disrupt the folding of IgFLNa23
also obliterated FLNa-FilGAP interaction.
The FLNa-binding site of FilGAP is followed by the coiled-
coil domain
We previously mapped the FLNa-binding domain of FilGAP to
its C-terminal 100 residues (649–748aa) which were predicted to
form a coiled-coil structure [12]. Although EMBnet COILS
program predicts three alternative coiled-coil segments (649–725,
648–729, 645–735), the biochemical data suggests that the
minimum FLNa-binding site is not a coiled-coil because the last
32 residues (717–748) do not dimerize, and FilGAP lacking
residues 648–725 is monomeric. Hence, these data indicate that
the FLNa interaction site on FilGAP is outside of the coiled coil
region and is available for the FLNa binding.
FilGAP interacts with the CD face of IgFLNa23
NMR titration experiments showed that FilGAP14 peptide
(residues 723–736) interact with the CD-face of IgFLNa23. This
interaction sequence is similar to the b-strand forming peptides of
platelet GPIba and integrins b1, b2, b3 and b7 that interact with
the corresponding faces of IgFLNa17 and IgFLNa21 [14–16]. In
the binding interface between FLNa and FilGAP, the amino acids
indicated with asterisks in Figure 3D (Phe726, Thr728, Gly730,
Leu732, and Val734) face the groove formed between the C and D
strands of the IgFLNa repeat, similar to the binding interaction of
GPIba and the b-integrins with FLNa. Further evidence for
FilGAP’s use of a similar binding motifs are: 1) Phe726, Leu732,
and Val734 in the FilGAP binding site are identical to the
corresponding amino acids of GPIba, which make strong
hydrophobic contacts with FLNa [14]; and 2) the amino acid
positions corresponding to Thr728 and Gly730 in FilGAP vary
between GPIba and integrin b. Serine occupies this position in
GPIba, and in most of the integrin b chains, and fits within the
FilGAP-FLNa interface. The small size of Gly730 would not be
expected to disrupt binding.
Figure 4. Point mutations of FLNa and FilGAP confirms the in
silico model of their binding interaction. (A) A point mutation in
FLNa (M2474E) abolishes the complexing of FLNa and FilGAP. The
upper panel shows amylose beads coated with MBP-FilGAP649-748
pulls down wild-type FLNa but not FLNaM2474E. The lower panel
shows wild-type (WT) FLAG-FLNa immobilized on FLAG-specific mAb
immobilized on agarose beads, but not FLAG-FLNaM2474E, pull down
full-length FilGAP. (B) FLAG-FLNa does not pull point mutants of FilGAP
at G730W and V734Y. T728V mutation has no effect on the interaction.
doi:10.1371/journal.pone.0004928.g004
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IgFLNa17-GPIba and IgFLNa21-integrin b7 complexes, we
proposed a model for the interaction, and we verified it by
introducing point mutations in both repeat 23 of full length FLNa
and in FilGAP. The effects of G730W and V734Y mutations on
the interaction suggest that these residues point towards the
interface, as predicted in our model (Figure 3C). Because the P736
residue is at the end of modeled b strand, alignments where the
peptide would be slipped backwards are not possible (Figure 3D).
Alternatively, slipping the peptide forward would bring V734 to a
position where mutation would not affect the interaction.
Higher order structure of the FLNa-FilGAP complex
Complexing of FilGAP with FLNa is not simply defined by the
binding interface, because the interaction is diminished by deletions
of 1) dimerization domain IgFLNa24, 2) FLNa hinge 2, and 3)
FilGAP coiled-coil domain. The coiled-coil domain of FilGAP is a
decamer when fused to an MBP-His tag, presumably because
coiled-coil domains aggregate in a variety of conformations [17].
However, full-length FilGAP and FilGAP lacking its coiled-coil
domain (residues 649–725) elute as a dimer and a monomer,
respectively, on a gel filtration chromatography. Residues 649–729
do not bind FLNa, indicating that the coiled-coil interaction
functions only to dimerize FilGAP. These data also suggest that
FilGAP domains other than the coiled-coil domain allow dimer-
ization while preventing oligomerization. Although NMR detects
interaction of IgFLNa23 with FilGAP peptide, neither monomeric
IgFLNa23 nor FilGAP biochemically pulled each other down,
indicating that their affinities for each other are very low. Binding
strength or avidity of macromolecules is governed by three major
factors: the intrinsic affinity of the individual binding interface, the
valency of the binding site(s), and geometric arrangement of the
interacting components [11,18]. We have previously shown that
dimerization of FLNa increases its affinity for F-actin by at least one
order of magnitude. Considering that the apparent dissociation
constant of FLNa-FilGAP of ,0.2 mM requires (assessed from ref.
[11]), FLNa and FilGAP each to be dimers, and IgG antibody
molecules bind ,1000 times more strongly than monovalent Fab
subfragments to a antigen [18], the dissociation constant of
IgFLNa23-FilGAP peptide interaction would be ,200 mM
(0.26,1000), making it difficult to detect in pull down assays.
Our data demonstrated that IgFLNa24 and the coiled-coil domain
of FilGAP mediate dimerization of FLNa and FilGAP, respectively,
and define their geometric arrangements and valencies, thereby
Figure 5. In vivo interaction of FLNa and FilGAP. (A) Immunoprecipitation of the FLNa/FilGAP complex expressed in FLNa-deficient M2 cells.
Wild-type or mutant (M2474E) FLNa were co-expressed with wild-type or mutant (V734Y) HA-tagged FilGAP in M2 cells. FLNa was
immunoprecipitated with FLNa-specific mAb and bound HA-FilGAP was detected by immunoblotting using HA-specific mAb. (B and C) Effects of
wild-type and mutant FilGAP on cell spreading. M2 cells were transfected with EGFP-FLNa, wild-type or V734Y mutant HA-FilGAP. After 48 h, cells
were trypsinized, plated on coverslips coated with fibronectin, and fixed at 15, 30, 60, and 120 min after plating. Cells were stained with mouse mAbs
to HA for FilGAP (red, three lower right panels) or Texas-red phalloidin for F-actin (red, lower left panel). FLNa was detected with EGFP (green, upper
panels). Stained cells at 120 min after plating are shown in (B). Scale bar, 50 ı `m. The percentages of spread cells were plotted as the mean6SEM
(n=3) in (C).
doi:10.1371/journal.pone.0004928.g005
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hinge 2 (32aa residues) does not contribute to valency but defines
the configurations that favor FilGAP binding (Figure 8). Electron
micrographs of purified FLNa-FilGAP complex are consistent with
the model.
Although no posttranslational modifications have been found so
far in the FLNa-FilGAP binding sites, their higher order structure
shown in Figure 8 suggests a possible mechanism for the regulation
of this interaction by mechanical force. Our recent studies
demonstrated that FLNa crosslinks F-actin using the conserved
srABD and the second ABD that locates in rod segment 1
(rs1ABD), whereas the rod segment 2 is free from F-actin and
accommodates the FilGAP interaction [11]. In addition, the
geometry of IgFLNa23 defines its binding strength to FilGAP,
suggesting that stretching or pushing of FLNa subunits attached to
an F-actin network that is subjected to external or internal forces in
vivo changes the geometry of two IgFLNa23 in FLNa dimer, hence
affecting the avidity of the complex. The low stoichiometry of
FLNa-FilGAP interaction determined in vitro and in cells (,0.02,
assessed from ref. [11,12]) is in agreement with this idea. This
mechanism may be in part responsible for FLNa’s reported role in
cellular mechanoprotection [19].
Figure 6. FilGAP specifically interacts with FLNa isoform. (A) Full-length FLNa, but not FLNb, pulls down FilGAP. Increasing amounts of either
FLNa or FLNb were incubated with FilGAP and immunoprecipitated with mAbs to FLNa or FLNb. Bound FilGAP was detected by immunoblotting
using rabbit pAbs to FilGAP. (B) MBP-FilGAP649-748 specifically binds the C-terminal of FLNa, but not FLNb or FLNc. Equal amounts of repeats 23–24
of FLNa, b, or c (0.2 ı `M) were pulled down with increasing amounts of MBP-FilGAP659-748. Proteins were visualized by CBB staining (top and bottom).
The top CBB-stained gel was destained and restained with silver (middle). (C) Sequence alignment of the C–E strands of the IgFLN23 isoforms. FLNa
A2461T, M2474E and Y2483H point mutants do not interact with FilGAP as shown in Figures 4A, 5A and 6E. (D) Model of the IgFLNa23-FilGAP
complex. Residues mutated in this study and some critical residues for their interaction are indicated. The purple dotted line shows the possible
stabilizing hydrogen-bond between Tyr2483 and Thr733. (E) A point mutation of FLNa at Ala2461 to Thr or Tyr2483 to His are sufficient to abolish the
complexing of FLNa and FilGAP. Full-length FilGAP (input: 10 nM constant) was pulled down with increasing amount of GST-IgFLNa20-24
immobilized on glutathione beads in a dose-dependent fashion. Mutations corresponding to A2461T or Y2483H in FLNa, but not D2467E, disrupt
FilGAP binding. Bound FilGAP was detected by immunoblotting using rabbit pAbs to FilGAP. GST-FLNa constructs were detected by CBB staining.
doi:10.1371/journal.pone.0004928.g006
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Overexpression of wild-type FilGAP in cells has been shown to
abolish integrin-mediated cell spreading, and a mutant FilGAP
lacking its C-terminal 100 residues does not colocalize with FLNa
in lamellae [12]. In this study we generated a FilGAP(V734Y)
point mutant sufficient to disrupt FLNa-binding while keeping the
coiled-coil domain intact. Consistent with a previous report, wild-
type FilGAP suppressed lamella formation and cell spreading. Co-
expression of EGFP-FLNa with wild-type FilGAP but not with the
mutant FilGAP(V734Y) reduced the suppression effect, presum-
ably because the mutant FilGAP unable to bind FLNa diffuses
throughout cell and suppresses Rac-activity broadly. These results
suggest that the binding of FilGAP to FLNa is important for
proper spatiotemporal control of FilGAP functions.
FilGAP is the first FLNa specific interaction partner
A mouse model and human developmental anomalies associ-
ated with FLNa mutations suggest that FLN isoforms have both
redundant and distinct functions in cells and in situ due to their
overlapping and unique distributions and partnering function
[9,20–24]. Here we found that FilGAP specifically interacts with
FLNa, whereas FLNb and FLNc sequences are quite similar to
FLNa and some binding partners interact with multiple filamin
isoforms [25]. Specificity is conferred by single substitutions of
amino acids at Ala2461 to Thr and Tyr2483 to His in FLNb and
c, respectively.
Disease-related FLNa mutations
Biological and rheological data suggest that two human disease-
causing mutations (D7 and D3) impact on both signal transduction
and mechanical deformation of cells. Since several binding
partners have been reported to interact with the C-terminus of
FLNa molecule, these mutations may perturb their interaction as
well [1,26]. However, our data demonstrate that these mutations
completely disrupt FLNa interaction with FilGAP, suggesting that
the D7 and D3 mutations at least perturb downstream of Rac,
thereby affecting cell spreading. The F-actin-FLNa networks
stiffen as they are strained [27], preventing large deformations that
could threaten cellular integrity. Indeed, substantial mechanical
stress induces apoptosis of FLNa-null cells [19]. The reduction of
Figure 7. Effect of disease-related mutations in repeat 23 of FLNa on FilGAP binding. (A) Amino acid sequence of human IgFLNa23. Point
(L2439M) and deletion (A ¨7 and A ¨3) mutants of FLNa are linked to human diseases and shown in underline. Box arrows indicate a ˆ-sheet strands. (B)
Rheological properties of the FLNa mutants. Left panel, Apparent viscosity of 24 ı `M actin polymerized with the indicated molar ratios of wild-type and
mutant FLNa. Error bars indicate SEM from triplicates. Right panel, Maximum shear stress supported by 12 ı `M F-actin polymerized with or without
0.06 ı `M wild-type and mutant FLNa. Error bars indicate s.d. from triplicates. The linear and nonlinear rheological properties are provided in (Figure S6).
(C) In vitro binding of recombinant human FLAG-FLNa and FilGAP purified from Sf9 insect cells. FilGAP was incubated with increasing amounts of
wild-type or mutant FLNa and the complex was co-immunoprecipitated with FLAG-specific mAb immobilized on agarose beads. Bound proteins
were detected by immunoblotting.
doi:10.1371/journal.pone.0004928.g007
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mutations, therefore, might affect cell survival under large
mechanical stress.
The FLNa L2439M mutation does not affect FilGAP binding
and rheological properties of F-actin/FLNa networks, which
might explain why the presence of two different aberrant
transcripts (L2439M and D7) in one patient exhibits overlap of
PVNH and FMD. The results also suggest that some FLNa-
binding partners interact with the strand A loop, where L2439M
locates, instead of a groove of strand C and D of IgFLNa repeat
which is the only binding interface characterized so far [14,15].
In conclusion, by employing biochemical, computer modeling,
and NMR analysis, which complement each other, we have
depicted a higher-order structure of the FLNa-FilGAP complex.
The structure explains how disease-causing mutations affect the
complexing and mechanical properties of FLNa-actin networks,
and suggests a novel mechanism of the regulation of FLNa-FilGAP
interaction. Although we focused on the structure of the FLNa-
FilGAP complex among over 50 binding partners identified thus
far, this study reports first functional validation of FLNa-partner
interactions in diseases using specific reagents informed by
structural analysis.
Materials and Methods
Protein expression and purification
FLAG-tagged full-length FLNa was expressed using a Baculo-
virus Expression System (Invitrogen) in Sf9 insect cells and purified
as previously described [11]. GST-His-FilGAP or MBP-His-
FilGAP constructs were made by inserting PCR products of
FilGAP domains to pGEX-4T-3-HT or pMALc-HT vectors [11],
expressed in E. coli, and purified using glutathione, amylose, or Ni-
NTA affinity columns as previously described [11]. Human full-
length FilGAP fused to His-tag was expressed in Sf9 cells and
purified using Ni-NTA affinity column. Tag-free FilGAP was
prepared from His-FilGAP using TEV protease. His-tag FilGAP
lacking 649–725 was expressed in E. coli (BL21(DE3)) using
pET23-HTa vector [11] and purified by Ni-NTA affinity and
Superose 6 gel filtration chromatography. GST-FLNa20-24 was
expressed in E. coli using pGEX-4T-1 vector and purified by
glutathione-Sepharose affinity chromatography. All the point or
deletion mutants were generated using the QuickChange site-
directed mutagenesis kit (Stratagene). His-IgFLNb23-24 was
expressed in Sf9 cells and purified using Ni-NTA affinity column.
After TEV cleavage, IgFLNb23-24 was gel filtered on Super-
dex200 10/300 column (GE healthcare). IgFLNc23-24 was
prepared as previously described [28].
13C
15N-IgFLNa23 and
15N-IgFLNa23 mutants were produced in E. Coli as previously
described [14]. For NMR studies the protein samples were
buffered to pH 6.8 with 20 mM sodium phosphate. The samples
also contained 150 mM NaCl, 1 mM DTT, 2 mM NaN3 and 7%
(vol/vol) D2O.
Structure determination
NMR experiments for structure determination were recorded
on Varian INOVA 500 MHz, 600 MHz and 800 MHz spec-
trometers equipped with 5 mm inverse z-gradient triple resonance
probe heads at 25uC. The structure determination was performed
with 1 mM
13C
15N-labeled IgFLNa23 sample. VNMR 6.1C
software was used in spectrum acquisition and processing (Varian
Inc., Palo Alto, CA). The triple-resonance experiments recorded
for backbone resonance assignment were iHNCA and iHNCACB,
HNCA, HN(CO)CA, HNCACB, HN(CO)CACB and HNCO
[29–31]. The side-chain resonance assignment for aliphatic
residues was done using CC(CO)NH and HCCH-COSY spectra.
The aromatic side-chain resonances were assigned using the
distance information from
13C-edited three-dimensional NOESY
spectrum. Structural restraints were extracted from
13C- and
15N-
edited three-dimensional NOESY spectra. The spectrum visual-
ization software Sparky 3.110 was used in spectrum analysis [32].
Structure determination was done with the automatic NOE
assignment mode of CYANA 2.1 software [33]. The set of 20 best
structures selected after torsion angle dynamics calculation were
refined with molecular dynamics in AMBER 8.0 using generalized
Born implicit solvent model [34]. The quality of the refined
structures was analyzed by using the WHAT_CHECK [35] and
PROCHECK [36]_NMR programs. Ramachandran plot statis-
tics for the ensemble of 20 refined structures: most favored, 91.1%;
Figure 8. Model of the FLNa-FilGAP complex. (A) Schematic
diagram of geometry of the FilGAP/FLNa/F-actin complex, suggesting
mechanical regulation of FilGAP binding to FLNa by shear stress to
FLNa/F-actin networks. (B) Schematic diagram of the proposed
structure of the C-terminal domains of the FLNa-FilGAP complex.
Atomic structure of the IgFLNa23 (blue) complexed with FilGAP peptide
(red) is shown in Figure 3C. FLNa and FilGAP are dimerized through
repeat 24 (cyan) and coiled-coil domain (magenta), respectively,
contributing high avidity binding. The hinge-2 (black) accommodates
proper geometry of their binding interface.
doi:10.1371/journal.pone.0004928.g008
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figures representing the protein structure were generated with
MOLMOL [37] and PyMOL [38].
The folding state of IgFLNa23 mutants L2439M and M2474E
was confirmed using
15N-HSQC spectra. The protein concentra-
tions of the IgFLNa23-L2439M and IgFLNa23-M2474E NMR
samples were 0.1 mM and 1 mM, respectively. The
15N-HSQC
spectrum of IgFLNa23-M2474E was recorded on Varian INOVA
600 MHz spectrometer at 25uC. The
15N-HSQC spectrum of
IgFLNa23-L2439M was recorded on Varian INOVA 600 MHz
spectrometer equipped with 5 mm cryo probe at 25uC.
FilGAP titration
The NMR titration experiments were performed with 0.5 mM
13C
15N-labeled IgFLNa23 sample. The FilGAP peptide (Fil-
GAP14: sequence
723EQFFSTFGELTVEP
736) was purchased
from EZBiolab Inc. A concentrated solution (5 mM) of FilGAP
peptide was prepared in protein buffer and pH was adjusted to 6.8
with 1 M NaOH. The titration experiments were performed on
Varian INOVA 500 MHz spectrometer equipped with 5 mm
inverse z-gradient triple resonance probe head at 25uC.
In silico modeling
The structure-based sequence alignment of IgFLNa23 and
IgFLNa17 was made with Bodil [39]. The X-ray structure of
IgFLNa17-GPIba complex (pdb-code: 2BP3) [14] was used as a
template structure to model the IgFLNa23 into peptide-binding
conformation. The three-dimensional model of IgFLNa23-
FilGAPC32 complex was constructed with Modeller 9v1 [40].
Coiled-coil domain structure was predicted by EMBnet COILS
(http://www.ch.embnet.org/software/COILS_form.html). Se-
quence alignment was generated using ClustalW program
(http://www.ebi.ac.uk/Tools/clustalw2/index.html).
FLAG-FLNa pull-down assay
Various concentration of GST-His- or MBP-His-FilGAP
constructs were incubated with 10 ml of FLAG-specific mAb M2
agarose (50% vol/vol slurry, Sigma) in the presence or absence of
25 nM FLAG-FLNa and in binding buffer (50 mM Tris-HCl,
150 mM NaCl, 0.1% (wt/vol) Triton X-100, 0.1 mM b-
mercaptoethanol, 0.1 mM EGTA, pH 7.4; 400 ml) for 1 h at
25uC. The beads were sedimented and washed 3 times with
binding buffer. Proteins bound to the beads were solublized in
SDS sample buffer and separated by 9.5% or 12.5% (wt/vol) SDS-
PAGE followed by immunoblotting using rabbit polyclonal
antibodies (pAbs) against GST (Sigma), MBP (New England
Biolabs), or FilGAP [12] or mouse mAb against His conjugated
with horse radish peroxidase.
In vitro immunoprecipitation
Purified FilGAP (50 nM) were incubated with increasing
amounts of either FLNa or FLNb in binding buffer and co-
immunoprecipitated with mouse mAb to FLNa (5 mg each of 3-14
and 4-3) [11] or FLNb (10 mg of 1-11c) [14] immobilized on 20 ml
of GammaBind G-Sepharose beads (GE healthcare) for overnight
at 4uC. The beads were sedimented and washed 3 times with
binding buffer. Proteins bound to the beads were solublized in
SDS sample buffer and separated by 9.5% (wt/vol) SDS-PAGE
followed by immunoblotting using rabbit pAbs to FilGAP.
MBP-FilGAP pull-down assay
FLNa or its truncates were incubated with 30 ml of amylose
resin (50% vol/vol slurry, New England Biolabs) coated with
various concentration of MBP-FilGAP 649–748 in the binding
buffer for 1 h at 25uC. The beads were sedimented and washed 3
times with binding buffer. Proteins bound to the beads were
solublized in SDS sample buffer and separated by 9% or 12.5%
(wt/vol) SDS-PAGE. Polypeptides in the gels were visualized by
Coomassie brilliant blue (CBB) staining or immunoblotting.
FLNa and FilGAP mammalian expression vectors
The ClaI/XbaI FLNa fragment of pEGFP-FLNa [14] vector
was cloned into pBluescript II SK vector, mutated using the
QuickChange site-directed mutagenesis kit, and then cloned back
to pEGFP-FLNa or pREP4-FLNa[41] vectors. The pCDNA5-
HA-FilGAP [12] was directly mutated using the QuickChange
site-directed mutagenesis kit.
Cell culture and immunoprecipitation
Human melanoma FLNa-deficient cell lines (M2) were
transfected with the pCDNA5-HA-FilGAP (wild-type or V734Y)
and the pREP4-FLNa (wild-type or M2474E) using FuGENE 6 as
described by the manufacturer’s instructions (Roche applied
science). Forty-eight hours later, the cells were rinsed three times
with PBS and lysed in 50 mM Tris-HCl, 150 mM NaCl, 1% (wt/
vol) TritonX-100, 1 mM b-mercaptoethanol, 5 mM EGTA, 10
ı `g/ml leupeptin, pepstatinA, aprotinin, 2 mM PMSA, 0.1 mg/ml
DNAseI. The cell lysates were pre-cleared and subjected to
immunoprecipitation with antibodies to FLNa [42] to precipitate
transfected FLNa. Bound protein was detected by western blotting
using mouse mAbs to FLNa for FLNa and rat mAb to HA (Roche
applied science) for FilGAP.
Cell spreading assay
M2 cell lines were transfected with the pCDNA5-HA-FilGAP
(wild-type or V734Y) and/or pEGFP-FLNa [14] using FuGENE
6. After 48 h, cells were trypsinized and plated on coverslips
coated with 10 ı `g/ml human fibronectin (Sigma) and fixed at
indicated time with 3.7% (wt/vol) formalin in PBS for 20 min.
The fixed cells were permeabilized with 0.5% (wt/vol) Triton X-
100 in PBS for 5 min and blocked with 0.2% (wt/vol) BSA, 0.1%
(wt/vol) sodium azide and 0.1% (wt/vol) Triton X-100 in PBS for
1 h. HA-FilGAP was stained with mouse mAb to HA (HA-7,
Sigma) at 1:500 dilution and mouse IgG-specific goat pAbs
conjugated with Alexa-568 (Invitrogen) at 1:400 dilution. Spread
cells were examined as described previously [12].
Gel-filtration Analysis
Purified FLNa constructs were loaded on a Superose 6 10/300
GL column (GE healthcare) and eluted at a flow rate of 0.4 ml/min
in 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5 mM EGTA,
0.5 mM b-mercaptoethanol at 4uC. Molecular size standards used
were thyroglobulin (669 kDa), ferritin (440 kDa), aldolase
(158 kDa), conalbumin (75 kDa), and ovalbumin (43 kDa).
Rheology
To probe the mechanical properties of F-actin-/FLNa net-
works, we employed a stress-controlled mechanical shear rheom-
eter (Bohlin, Malvern Instruments) equipped with a 40-mm
parallel plate geometry and a gap of 100 mm as previously
described [27]. Briefly, 12 mM monomeric actin was mixed with
0.06 mM wild-type or mutant FLNa and polymerization buffer
(total volume 150 mL) and immediately placed between the
stainless steel plates of the rheometer. The sample was allowed
one hour to polymerize before measuring the dynamic viscoelastic
moduli.
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Accession codes
The resonance assignments and the distance restraints used in
IgFLNa23 NMR structure calculation have been deposited in
BioMagResBank under accession number 15777. The coordinates
of the structure ensemble have been deposited in Protein Data
Bank under accession code 2k3t.
Supporting Information
Figure S1 Physical properties of the recombinant proteins. (A)
Coomassie blue stain of 8–16% gradient Tris-Glycine SDS-PAGE
of each purified recombinant protein (0.5 mg). (B) Gel filtration
analysis of FilGAP constructs on Superose6 10/300 GL. Apparent
molecular weight (Mr) were determined from elution volumes by
comparing to those of throglobulin, ferritin, aldorase, conalbulin,
ovalbumin, and ribonuclease A (left to right).
Found at: doi:10.1371/journal.pone.0004928.s001 (8.97 MB TIF)
Figure S2 Electron micrographs of the purified FLNa and its
mutants. Structure of full-length FLNa and mutant FLAG-FLNa
were determined by low angle rotary shadowing of molecules
sprayed onto mica and dried under vacuum.
Found at: doi:10.1371/journal.pone.0004928.s002 (3.72 MB TIF)
Figure S3 NMR titration of FilGAP peptide to IgFLNa23. (A)
15N-HSQC spectrum of IgFLNa23+660%FilGAP14 (blue) super-
imposed on 15N-HSQC spectrum of IgFLNa23 (red). (B)
Chemical shift changes in the 15N-HSQC spectrum of IgFLNa23
upon addition of 6.6-fold excess of FilGAP14 as a function of
sequence. Black=overlapping signal which could not be traced
reliably. Light gray=signal has broadened beyond detection or it
has divided into multiple peaks. The chemical shift difference was
set to 0.22 ppm.
Found at: doi:10.1371/journal.pone.0004928.s003 (6.83 MB TIF)
Figure S4 Comparison of IgFLNa23, IgFLNa17 and
IgFLNa17-GPIba complex. Based on the X-ray structure of
IgFLNa17-GPIba complex (pink ribbon), it was possible to build a
model for IgFLNa23-FilGAPC32 complex (not shown) where the
IgFLNa23 is in such conformation that it can bind the FilGAPC32
peptide. When compared to the NMR structure of IgFLNa23
(gray ribbon) and IgFLNa17 (cyan ribbon), peptide binding seems
to force the C and D strands further away from each other,
especially between the N-terminus of C strand and C-terminus of
D-strand. The binding of FilGAP peptide to IgFLNa23 reflects at
the structural level particularly to the conformation of the Y2483
side-chain that is pushed aside to allow the binding of peptide
binding. Chemical shift changes of Y2483 are seen in the FilGAP
peptide NMR titration experiments (Figure 3 and Figure S3).
Found at: doi:10.1371/journal.pone.0004928.s004 (6.29 MB TIF)
Figure S5 Chemical shift changes induced to the 15N-HSQC
spectrum of IgFLNa23 by M2474E mutation. (A) Superimposition
of the 15N-HSQC spectra of IgFLNa23 (red) and M2474E
IgFLNa23 (blue). (B) Chemical shift difference as a function of
sequence. Black=mutated residue, light gray=signal has shifted
too much to be identified without complete reassignment. The
chemical shift difference was set to 0.4 ppm. (C) Chemical shift
differences exceeding 0.1 ppm mapped on the structure of
IgFLNa23. The mutated residue is indicated with stick model.
Found at: doi:10.1371/journal.pone.0004928.s005 (9.30 MB TIF)
Figure S6 Rheological properties of 12 mM F-actin networks
cross-linked with 0.06 mM purified FLNa and its mutants. (A) The
linear elastic moduli, G9 (closed circles), and viscous moduli, G9
(open circles), as a function of frequency. (B) The nonlinear elastic
moduli as a function of strain, measured at f=0.1 Hz. (C) The
nonlinear elastic moduli as a function of applied stress, measured
at f=0.1 Hz.
Found at: doi:10.1371/journal.pone.0004928.s006 (7.49 MB TIF)
Figure S7 Chemical shift changes induced to the 15N-HSQC
spectrum of IgFLNa23 by L2439M mutation. (A) Superimposition
of the 15N-HSQC spectra of IgFLNa23 (red) and L2439M
IgFLNa23 (blue). (B) Chemical shift difference as a function of
sequence. Black=mutated residue, light gray=signal has shifted
too much to be identified without complete reassignment. The
chemical shift difference was set to 0.4 ppm. (C) Chemical shift
differences exceeding 0.1 ppm mapped on the structure of
IgFLNa23. The mutated residue is indicated with stick model.
Found at: doi:10.1371/journal.pone.0004928.s007 (9.27 MB TIF)
Figure S8 Electron micrographs of the purified FLNa and
FilGAP. Rotary shadowed images of purified FilGAP (top), FLNa
(second from the top), the FLNa/FilGAP complex (third from the
top), mutant FLNaM2474E mixed with FilGAP (the second from
the bottom), and FLNaM2474E (bottom). FLNa and FilGAP were
mixed at a 1FLNa:20FilGAP ratio for 1 h end-over-end at room
temperature, diluted 1:4 in 67% glycerol to a final protein
concentration of 25 mg/ml (50% glycerol), and sprayed onto mica
as previously described1. About 26% (26 / 100) of wild-type FLNa
molecules were complexed with FilGAP, whereas FLNaM2474E
mutant molecules were not.
Found at: doi:10.1371/journal.pone.0004928.s008 (3.60 MB TIF)
Table S1 NMR and refinement statistics for IgFLNa23.
Found at: doi:10.1371/journal.pone.0004928.s009 (1.69 MB TIF)
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